The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Nurx, a leading telehealth platform specializing in women's health, is excited to announce an integration agreement with ...

States that do provide coverage have tried to manage costs by putting prescribing limits on the GLP-1s. There’s also some ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...

That's why Veeva Systems should remain a leader in its niche and deliver excellent returns over the long run. It's a top stock to buy and hold for the next two decades.

Proponents of coverage argued treating obesity can reduce longer-term costs by cutting down on heart attacks and other health ...